Why targeted protein degradation is redefining drug development
Targeted protein degradation represents a fundamental shift in how small molecules interact with disease biology. For six decades, small molecule drug development has focused on occupying enzyme active sites or receptor binding pockets to inhibit biological function. This approach is powerful but constrained: only proteins with druggable binding sites — pockets that can accommodate a small molecule with sufficient affinity and selectivity — are accessible. Approximately 80% of the human proteome is considered "undruggable" by conventional inhibitor approaches, including transcription factors, scaffold proteins, and proteins whose pathological role depends on protein-protein interactions rather than enzymatic activity.
PROTACs and molecular glues circumvent this constraint by reframing the goal: instead of blocking a protein's activity, destroy the protein entirely. The ubiquitin-proteasome system (UPS), which cells use to degrade misfolded and excess proteins, becomes the therapeutic mechanism. A degrader molecule creates a proximity-induced interaction between the target protein and an E3 ubiquitin ligase — tagging the target for proteasomal destruction. This approach opens new therapeutic possibilities for previously intractable targets.
Get daily protein degrader trial alerts
Every enrollment update, protocol amendment, and new PROTAC/degrader trial — delivered to your inbox each morning.
Sign Up FreeARV-471 (vepdegestrant): the first PROTAC in Phase 3
Arvinas' ARV-471 (now named vepdegestrant) is the most advanced PROTAC in clinical development, having entered Phase 3 in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer. ARV-471 is a bifunctional PROTAC that recruits Cereblon (CRBN) to the estrogen receptor (ER), directing ER for proteasomal degradation. Estrogen receptor is the primary driver of HR+ breast cancer and the target of the most important breast cancer drugs: fulvestrant (selective estrogen receptor degrader), tamoxifen (SERM), and aromatase inhibitors. ARV-471 achieved deep ER degradation (greater than 90% receptor loss in tumor biopsies), clinical response rates comparable to fulvestrant in Phase 2, and activity in patients with ESR1 mutations — the most common mechanism of acquired fulvestrant resistance.
The VERITAC-2 Phase 3 trial is a global registrational study comparing ARV-471 head-to-head against fulvestrant in patients with metastatic HR+/HER2- breast cancer who have progressed on at least one prior endocrine therapy plus a CDK4/6 inhibitor. This head-to-head design is a high-stakes clinical strategy: a positive trial would establish the first PROTAC as a standard-of-care breast cancer drug, validate the degrader mechanism, and unlock an enormous commercial opportunity (the post-CDK4/6 inhibitor breast cancer market is one of the largest in oncology).
Pfizer partnered with Arvinas on ARV-471 in a deal worth up to $1.425 billion plus royalties — the largest PROTAC partnership in the industry at the time — underscoring the commercial conviction in the ER-degrader hypothesis.
ARV-766: PROTAC AR degrader in prostate cancer
Arvinas' second late-stage PROTAC targets the androgen receptor (AR) in metastatic castration-resistant prostate cancer (mCRPC). ARV-766 uses the VHL E3 ligase (rather than CRBN) to degrade AR, achieving broader degradation of AR splice variants — including AR-V7, the most clinically relevant AR variant associated with enzalutamide and abiraterone resistance — compared to existing AR antagonists. Phase 2 data showed ARV-766 clinical activity in heavily pre-treated mCRPC patients including those with AR-V7-positive disease. The Phase 3 program positions ARV-766 as a potential next-line option after failure of approved AR antagonists.
Molecular glues: CELMoDs in hematology
Cereblon E3 Ligase Modulators (CELMoDs) are Bristol Myers Squibb's proprietary molecular glue platform, building on the mechanism of lenalidomide and pomalidomide. First-generation IMiDs (immunomodulatory drugs) bind CRBN and induce degradation of IKZF1 and IKZF3 transcription factors, with anti-myeloma and anti-lymphoma activity. CELMoDs are designed with improved potency, selectivity, and substrate specificity compared to first-generation IMiDs.
Iberdomide (CC-92480) is the most advanced CELMoD, in Phase 3 for relapsed/refractory multiple myeloma after multiple prior therapies including IMiDs and proteasome inhibitors. Iberdomide degrades IKZF1 and IKZF3 with greater potency than lenalidomide, showing activity in IMiD-resistant patients. BMS-986365 (mezigdomide) is a second CELMoD with enhanced IKZF1/IKZF3 selectivity, also in Phase 2/3. These drugs address the critical commercial problem of post-triplet therapy myeloma, a growing and underserved population as early-line regimens become more effective.
NX-5948: first BTK degrader in clinical trials
Nurix Therapeutics' NX-5948 is the first BTK (Bruton's tyrosine kinase) PROTAC degrader to enter clinical trials. BTK is validated as a target in B-cell malignancies and autoimmune disease: ibrutinib, acalabrutinib, and zanubrutinib (covalent BTK inhibitors) are approved for CLL, MCL, WM, and other B-cell cancers. However, BTK inhibitor resistance via C481 mutation is a significant clinical challenge, and BTK inhibitors are increasingly used in autoimmune diseases (RA, lupus, Sjögren's) where non-covalent engagement and intermittent dosing may be insufficient. BTK degradation via PROTAC would overcome C481 resistance (PROTACs work by induced proximity and don't require prolonged target occupancy), potentially providing activity in ibrutinib-resistant patients. NX-5948 is in Phase 1/2 in B-cell malignancies and autoimmune diseases.
CFT7455: CDK4 and CDK6 molecular glue degrader
C4 Therapeutics' CFT7455 is a molecular glue that induces co-degradation of CDK4 and CDK6 via the CRBN E3 ligase. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are foundational in HR+ breast cancer, but resistance is common. CFT7455 achieves deeper and more sustained CDK4/6 depletion than occupancy-based inhibitors, potentially overcoming resistance caused by CDK4/6 amplification or overexpression. Phase 1 data demonstrated CDK4 and CDK6 degradation in patient biopsies. Combination with endocrine therapy (aromatase inhibitors or ARV-471) is under exploration.
Active targeted protein degradation clinical trial pipeline
| Sponsor | Drug | Target / Mechanism | Indication | Phase |
|---|---|---|---|---|
| Arvinas / Pfizer | ARV-471 (vepdegestrant) | PROTAC — CRBN/ER degrader | HR+/HER2- breast cancer | Phase 3 |
| Arvinas | ARV-766 | PROTAC — VHL/AR degrader | mCRPC (post-enzalutamide) | Phase 2/3 |
| Bristol Myers Squibb | Iberdomide (CC-92480) | CELMoD / CRBN molecular glue (IKZF1/3) | Relapsed/refractory multiple myeloma | Phase 3 |
| Bristol Myers Squibb | Mezigdomide (BMS-986365) | CELMoD / CRBN molecular glue (IKZF1/3) | Relapsed/refractory multiple myeloma | Phase 2/3 |
| Nurix Therapeutics | NX-5948 | PROTAC — CRBN/BTK degrader | B-cell malignancies, autoimmune | Phase 1/2 |
| C4 Therapeutics | CFT7455 | Molecular glue — CRBN/CDK4/6 degrader | Breast cancer, CDK4/6-resistant | Phase 1/2 |
| Kymera Therapeutics | KT-474 | PROTAC — IRAK4 degrader | Atopic dermatitis, hidradenitis | Phase 2 |
| Kymera Therapeutics | KT-621 | PROTAC — STAT6 degrader | Type 2 inflammatory diseases | Phase 1 |
| Monte Rosa Therapeutics | MRT-2359 | Molecular glue — GSPT1 degrader | MTAP-deleted cancers | Phase 1/2 |
| Foghorn Therapeutics | FHD-609 | PROTAC — BRD9 degrader | Synovial sarcoma (SS18-SSX+ tumors) | Phase 1/2 |
Competitive landscape: who's building the PROTAC pipeline
The targeted protein degradation field has attracted significant large pharma investment through partnerships and acquisitions. Pfizer's $1.425B deal with Arvinas set the tone, followed by Novartis's acquisition of Molecular Partners' degrader technology, Roche's broad PROTAC collaboration with Arvinas, and multiple other strategic partnerships. AstraZeneca, Johnson & Johnson, and Merck all have internal or partnered PROTAC programs. The technical challenge of designing PROTACs with oral bioavailability, favorable pharmacokinetics, and selectivity across a complex three-body (PROTAC + target + E3 ligase) interaction space has proven substantial, which is why Arvinas' Phase 3 achievements represent a genuine milestone.
Track the protein degradation pipeline
DataLookout monitors every PROTAC and molecular glue trial on ClinicalTrials.gov. Get daily alerts when any degrader program changes. Free 14-day trial.
Start Free Trial